Nevertheless, the best-known field of application of CD38 as a pharmacological target is arguably represented by hematological malignancies: different anti-CD38 monoclonal antibodies have been developed and are currently in use or in clinical trials, especially in multiple myeloma [16,17]. This evidence concerns the gene CD38 and plasma cell myeloma.